Gyre Therapeutics, Inc.

GYRE Healthcare Biotechnology

In the quarter to June 2026, revenue fell 2.12%, EPS was flat and free cash flow fell 130.5%, each against the same quarter a year earlier.

6.08 0.32 −5.00%
Market cap
$678.6M
P/E
0.0×
Fwd P/E
−21.7×
Dividend yield
—
F-score
4/9
Altman Z
16.83
Beneish M
−2.02
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
0.00 0.00 0.00 — 0.00 0.00 0.00 0.00 86.43 141.20
Piotroski F-Score
2 4 4 — — — 8 4 5 4
Altman Z-Score
(6.50) (3.81) 8.65 — (1.65) (13.25) 26.41 25.08 23.76 16.83
P/S ratio
19.35 48.36 117.56 — 5.78 3.80 5.26 13.80 9.74 5.41
P/FCF ratio
0.00 0.00 0.00 — 0.00 0.00 98.87 87.15 0.00 0.00
Altman Z″-Score (non-manufacturers)
(12.82) (9.29) 24.45 — (5.67) (26.84) 9.96 (2.01) 5.15 8.71
P/Operating CF
(1.55) (7.79) (9.82) — (5.48) (1.58) 13.30 466.11 (373.33) (112.14)
Beneish M-Score
(3.91) — — — — — 9.51 (6.80) (1.20) (2.02)
P/B ratio
0.48 1.60 0.74 — 1.59 0.68 7.79 112.28 10.46 10.59
EV/Sales
(23.22) 16.39 (35.09) — 2.24 (1.87) 5.07 13.56 9.53 4.66
EV/EBITDA
0.46 0.00 0.78 — 0.00 0.16 52.54 0.00 56.80 38.79
EV/FCF
0.57 (0.84) 0.91 — (0.85) 0.16 95.36 85.58 (158.25) (615.37)
Current Ratio
1.71 4.48 25.83 3.32 5.03 3.63 4.06 2.85 3.32 5.60
Net Debt/EBITDA
0.86 1.51 3.57 1.35 1.39 0.53 (2.44) 0.51 (1.50) (3.74)
Debt/Equity
1.21 0.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE
(71.35%) (108.92%) (39.88%) (58.61%) (77.89%) (150.11%) 4.06% (215.71%) 21.51% 4.18%
ROA
(31.49%) (65.75%) (36.56%) (49.38%) (58.16%) (116.85%) 3.28% (92.34%) 9.99% 3.45%
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 12.23% (93.45%) 14.08% 7.99%
Return on Tangible Assets
(105.91%) (83.25%) (25.13%) (81.78%) (77.95%) (229.70%) 4.18% (153.70%) 17.48% 4.67%
Average Days of Receivables
28.36 0.00 0.00 0.00 57.73 90.43 61.15 52.92 85.52 98.02
Earnings Yield
(218.29%) (65.38%) (33.57%) — (44.83%) (315.23%) (44.04%) (12.78%) 1.16% 0.71%
Free Cash Flow Yield
(212.07%) (40.55%) (32.68%) — (45.69%) (303.37%) 1.01% 1.15% (0.62%) (0.14%)
Free Cash Flow per Share
(314.92) (87.40) (38.68) (54.55) (43.24) (41.39) 0.09 0.27 (0.07) (0.01)
Book value per Share
309.06 134.74 160.35 85.35 59.47 20.10 1.14 1.19 1.16 1.59
Free Cash Flow
(16.38) (19.96) (28.93) (43.68) (55.31) (84.59) 5.68 17.97 (6.37) (0.88)
EV/EBIT
0.45 0.00 0.78 — 0.00 0.16 58.98 0.00 62.38 47.30
Other line items

Show all line items

Columns are period end dates